Nectar Lifesciences Limited (NSE:NECLIFE)
10.68
+0.50 (4.91%)
Jul 31, 2026, 3:28 PM IST
Nectar Lifesciences Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 2,055 | 1,807 | 5,147 | 6,761 | 3,577 | 5,393 | |
Market Cap Growth | -44.86% | -64.90% | -23.88% | 89.03% | -33.68% | 29.30% |
Enterprise Value | 804 | 6,331 | 11,251 | 13,371 | 11,331 | 14,300 |
Last Close Price | 10.58 | 9.30 | 22.95 | 30.15 | 15.95 | 24.05 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | - | 135.37 | - | 21.53 |
PS Ratio | - | - | 0.31 | 0.40 | 0.24 | 0.32 |
PB Ratio | 0.35 | 0.31 | 0.54 | 0.63 | 0.34 | 0.50 |
P/TBV Ratio | 0.35 | 0.31 | 0.57 | 0.67 | 0.35 | 0.52 |
P/FCF Ratio | - | - | 4.10 | 3.46 | 3.45 | 7.70 |
P/OCF Ratio | - | - | 3.04 | 3.01 | 2.68 | 5.68 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | - | - | 0.67 | 0.79 | 0.74 | 0.86 |
EV/EBITDA Ratio | - | - | - | 8.71 | 21.00 | 9.02 |
EV/EBIT Ratio | - | - | - | 14.40 | - | 14.08 |
EV/FCF Ratio | - | - | 8.95 | 6.85 | 10.94 | 20.42 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | - | - | 0.61 | 0.59 | 0.71 | 0.79 |
Debt / EBITDA Ratio | - | - | - | 4.14 | 13.97 | 5.42 |
Debt / FCF Ratio | - | - | 4.63 | 3.26 | 7.28 | 12.28 |
Net Debt / Equity Ratio | -0.21 | -0.21 | 0.59 | 0.57 | 0.69 | 0.77 |
Net Debt / EBITDA Ratio | 4.32 | 4.32 | -21.56 | 4.01 | 13.64 | 5.31 |
Net Debt / FCF Ratio | 0.35 | 0.35 | 4.47 | 3.15 | 7.10 | 12.02 |
Asset Turnover | - | - | 0.79 | 0.77 | 0.67 | 0.70 |
Inventory Turnover | - | - | 1.83 | 1.62 | 1.60 | 1.78 |
Quick Ratio | 6.35 | 6.35 | 0.40 | 0.45 | 0.41 | 0.53 |
Current Ratio | 9.59 | 9.59 | 1.21 | 1.32 | 1.38 | 1.35 |
Return on Equity (ROE) | -7.46% | -7.46% | -11.23% | 0.47% | -2.25% | 2.33% |
Return on Assets (ROA) | -2.42% | -2.42% | -2.61% | 2.65% | -0.14% | 2.66% |
Return on Invested Capital (ROIC) | -6.36% | -5.24% | -5.52% | 1.46% | -0.28% | 3.86% |
Return on Capital Employed (ROCE) | -8.70% | -8.70% | -8.60% | 7.60% | -0.40% | 7.30% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -142.51% | -162.12% | -22.09% | 0.74% | -6.76% | 4.64% |
FCF Yield | -175.64% | -199.82% | 24.41% | 28.88% | 28.96% | 12.98% |
Buyback Yield / Dilution | 2.54% | 2.54% | - | - | - | - |
Total Shareholder Return | 2.54% | 2.54% | - | - | - | - |